Cargando...
The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer related mortality in the United States in 2030, with a 5-year overall survival of less than 10% despite decades of extensive research. Pancreatic cancer is marked by the accumulation of comple...
Gardado en:
| Publicado en: | Expert Rev Anticancer Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6121777/ https://ncbi.nlm.nih.gov/pubmed/29254387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2018.1417844 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|